Matthew J Pfeffer

CIK 1192063 · CEO, CFO, Director · last filed 2019-06-05

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$349.2K

Companies

Total Filings

Lifetime Open-Market Net

-$549.7K

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

MNKD price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest

OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
Vivani Medical, Inc. (EYESW) Delisted	Director	118,301	$0.22	$26.0K	$0	3	2019-06-05
MNKD	CEO, CFO, Director	81,961	$3.19	$261.9K	-$547.3K	34	2017-08-29
EYES	Director	2,880	$30.33	$87.4K	$0	2	2017-03-16
DS HEALTHCARE GROUP, INC. (DSKX) Delisted	Director	5,000	—	—	$0	1	2014-02-18
GENELABS TECHNOLOGIES INC /CA (GNLB) Delisted	Director	0	—	—	-$13.0K	3	2009-01-07
Diadexus, Inc. (AXC) Delisted	SENIOR VICE PRESIDENT AND CFO	20,000	—	—	$10.6K	2	2007-12-04

Recent Filings · Page 5 of 5

47 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2008-08-15	MNKD	Grant (A)	—	$0	EDGAR
2008-07-02	GENELABS TECHNOLOGIES INC /CA (GNLB) Delisted	Grant (A)	—	$0	EDGAR
2008-04-30	MNKD	Grant (A)	+4,500	$0	EDGAR
2007-12-04	Diadexus, Inc. (AXC) Delisted	Buy (P)	+10,000	$4.6K	EDGAR
2007-11-15	Diadexus, Inc. (AXC) Delisted	Buy (P)	+10,000	$6.0K	EDGAR
2007-07-31	GENELABS TECHNOLOGIES INC /CA (GNLB) Delisted	Grant (A)	—	$0	EDGAR
2007-02-14	—	Mixed	—	$0

Showing 41–47 of 47

Prev Page 5 of 5

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.